TheraRadar
Data updated: Mar 29, 2026

NOCTIVA

DESMOPRESSIN ACETATE
Approved 2017-03-03
Jump to: Indications Approvals Trials Competitors Safety Patents
1
Indication
--
Phase 3 Trials
9
Years on Market

Details

Status
Discontinued
First Approved
2017-03-03
Routes
NASAL
Dosage Forms
SPRAY, METERED

Companies

ACERUS PHARMS
Active Ingredient: DESMOPRESSIN ACETATE

NOCTIVA Approval History

Loading approval history...

What NOCTIVA Treats

1 FDA approvals

Originally approved for its first indication in 2017 .

  • Other (1)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

NOCTIVA FDA Label Details

Pro

NOCTIVA Patents & Exclusivity

Latest Patent: Jun 2030

Patents (12 active)

US11419914 Expires Jun 15, 2030
US12090190 Expires Jun 15, 2030
US9539302 Expires Jun 15, 2030
+ 2 more patents
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

FDA Approval: NDA201656 → Patents: FDA Orange Book → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.